Tetanus-Diphtheria-Acellular Pertussis Adsorbed-Inactivated Polio (Tdap-IPV)

ADACEL®-POLIO  Supplier: Sanofi Pasteur Limited
BOOSTRIX®-POLIO   Supplier: GlaxoSmithKline Inc.

INDICATIONS:

- School entry booster at 4-6 years of age. This is the 5th dose in a routinely immunized child.
- Completion of primary series for unimmunized or incompletely immunized children (7 years of age and older), adolescents and adults, including those with unknown immunization history, requiring protection against tetanus, diphtheria, pertussis and polio. A
- Select special populations as indicated in Part 2 - Immunization of Special Populations.

These vaccines are indicated as a booster dose for those 4 years of age and older, and are not intended for primary immunization for children less than 7 years of age.

DOSE(S) AND SCHEDULE: B

Booster dose at 4-6 years of age: 1 dose given as 0.5 mL IM. C

Children and Adolescents 7-17 years of age (inclusive): D

- Booster dose for those who missed receiving the school entry booster dose:
  o 1 dose given as 0.5 mL IM

- Incompletely immunized children and adolescents:
  o If the first dose of DTaP-containing vaccine was administered after the 1st birthday, administer additional dose(s) in order to complete a 3-dose primary series. Given as:
    ▪ Dose 1: 0.5 mL IM
    ▪ Dose 2: 0.5 mL IM 4-8 weeks after 1st dose
    ▪ Dose 3: 0.5 mL IM 6-12 months after 2nd dose

  o If the first dose of DTaP-containing vaccine was administered before the 1st birthday, administer additional dose(s) in order to complete a 4-dose primary series. E Given as:
    ▪ Dose 1: 0.5 mL IM
    ▪ Dose 2: 0.5 mL IM 4-8 weeks after 1st dose
    ▪ Dose 3: 0.5 mL IM 4-8 weeks after 2nd dose
    ▪ Dose 4: 0.5 mL IM 6-12 months after 3rd dose

A Tdap-IPV is the preferred product for this indication, but separate Tdap and IPV may be used.
B There is no minimum interval between a dose of Td and Tdap-IPV when Tdap-IPV is being given for pertussis and polio protection.
C Not necessary if the 4th dose of a DTaP or Tdap-containing vaccine was given after the 4th birthday.
D Children who complete their primary series, or receive a booster dose of Tdap, after their 10th birthday do not require an additional dose of Tdap in grade 9.
E As only 3 doses of polio are required, Tdap may be used as one of the doses in this series, ensuring the recommended intervals for polio are maintained.
Tetanus-Diphtheria-Acellular Pertussis Adsorbed-Inactivated Polio (Tdap-IPV)

**ADACEL®-POLIO**  
Supplier: Sanofi Pasteur Limited

**BOOSTRIX®-POLIO**  
Supplier: GlaxoSmithKline Inc.

### DOSES AND SCHEDULE (continued):

- **Unimmunized children and adolescents:**
  - 3 doses given as:
    - **Dose 1:** 0.5 mL IM
    - **Dose 2:** 0.5 mL IM 4-8 weeks after 1st dose
    - **Dose 3:** 0.5 mL IM 6-12 months after 2nd dose

- **Adults 18 years of age and older:**
  - Unimmunized or incompletely immunized adults completing a 3-dose series:
    - **First dose** given as Tdap-IPV, followed by 2 doses of Td/IPV, given as:
      - **Dose 1:** 0.5 mL IM
      - **Dose 2:** 0.5 mL IM 4-8 weeks after 1st dose
      - **Dose 3:** 0.5 mL IM 6-12 months after 2nd dose

### ADMINISTRATION:

No additional requirements.

### BOOSTER DOSES:

There are no routine additional doses of these vaccines required outside of the above indications.\(^A\)

### SEROLOGICAL TESTING:

Serological testing is not recommended before or after immunization.

### CONTRAINDICATIONS:

1. History of an anaphylactic reaction to a previous dose of tetanus, diphtheria, pertussis or polio vaccine or any component of ADACEL®-POLIO or BOOSTRIX®-POLIO.
2. History of Guillain-Barré syndrome (GBS) within 8 weeks of receipt of a tetanus-containing vaccine without any other cause being identified.

---

\(^A\) Refer to **Part 1 – Immunization Schedules** for information regarding booster doses using the age appropriate tetanus and diphtheria-containing vaccines.
Tetanus-Diphtheria-Acellular Pertussis Adsorbed-Inactivated Polio (Tdap-IPV)

**ADACEL®-POLIO**
Supplier: Sanofi Pasteur Limited

**BOOSTRIX®-POLIO**
Supplier: GlaxoSmithKline Inc.

**PRODUCT COMPONENTS:**

**ADACEL®-POLIO:**
Potential allergens: bovine serum albumin, neomycin, polymyxin B, streptomycin, polysorbate 80.
Other components: aluminum phosphate, 2-phenoxyethanol, ethanol, formaldehyde, glutaraldehyde.

**BOOSTRIX®-POLIO:**
Potential allergens: neomycin sulphate, polymyxin B sulphate.
Other components: aluminum (as aluminum salts), Medium 199.

**PRECAUTIONS:**
Not applicable.

**SPECIAL CONSIDERATIONS:**

- Any dose(s) of oral polio vaccine (OPV) received on or after April 1, 2016 will not be considered as a valid dose within the routine BC Immunization Schedule. For more information, see Part 4 – Biological Products, Polio Vaccine, Special Considerations.

- A history of two fractional doses of inactivated polio vaccine (fIPV) can be considered equivalent to a single IPV dose provided the first dose was given at a minimum age of 6 weeks with a minimum interval of 4 weeks between doses. For more information, see Part 4 – Biological Products, Polio Vaccine, Special Considerations.

**ADVERSE EVENTS:**

- **Local:** pain, redness, swelling.
- **Systemic:** fatigue, headache, fever, chills.